MIT’s new bacteria protects guts from antibiotic-caused dysbiosis

It keeps the microbiome in balance while letting the meds battle infections.

Starting with a bacteria used to make cheese, MIT and Harvard researchers are developing a treatment to protect the good bacteria in the gut from antibiotics — helping people battle infections without messing up their microbiome.

The good microbes: Your gastrointestinal tract is home to a unique collection of trillions of bacteria, viruses, and fungi. This is your gut microbiome, and everyone’s is different — exactly which microbes are in your belly depends on your genes, diet, environment, and other factors. 

The gut microbiome plays an important role in your health, helping you digest food, produce vitamins, and prevent infections. But if this ecosystem in your GI tract is thrown off — a condition called “dysbiosis” — it can contribute to many health issues, from short-term diarrhea to long-term GI problems.

Lots of medications can cause dysbiosis, including antibiotics. While fighting infections, antibiotics also kill helpful bacteria as collateral damage, including ones that compete with the microbe C. difficile. This may lead to a C. diff infection, which can cause recurring bouts of nausea, fever, severe diarrhea, and even death.

If the balance of microbes in your GI tract is thrown off, it can contribute to many health issues.

In an attempt to prevent dysbiosis, doctors may prescribe supplements that contain beneficial bacteria — probiotics — along with antibiotics, to try to restore the microbiome. 

But Andres Cubillos-Ruiz, lead author of the new study, believes they’re not an adequate solution to the problem.

“Standard probiotics cannot compare to the diversity that the native microbes have,” he said. “They cannot accomplish the same functions as the native microbes that you have nurtured throughout your life.”

While fighting infections, antibiotics also kill helpful bacteria as collateral damage.

Start with cheese bacteria: Cubillos-Ruiz and his colleagues have now created a bacteria that appears to protect the gut microbiome from dysbiosis without reducing the efficacy of antibiotics.

The researchers started by modifying a strain of a bacteria used to make cheese (L. lactis) to make an enzyme called beta-lactamase. This enzyme breaks down most kinds of antibiotics, called beta-lactams, which account for 60% of antibiotic prescriptions in the US.

Mice given this bacteria along with an antibiotic showed higher levels of microbial diversity in their microbiome (a potential sign of a healthy gut) than mice given antibiotics alone. Mice that got the bacteria treatment all ended up with lower levels of C. diff in their guts, too.

“Standard probiotics cannot compare to the diversity that the native microbes have.”

Andres Cubillos-Ruiz

The level of antibiotics in the bloodstreams of the mice, meanwhile, were the same regardless of whether they got the bacteria, suggesting that it wouldn’t interfere with the meds’ ability to fight infections outside the gut. 

The bacteria doesn’t affect antibiotic levels in the blood because most oral antibiotics are absorbed in the stomach, above the intestines where most gut bacteria live. 

“This is a strong demonstration that this approach can protect the gut microbiota, while preserving the efficacy of the antibiotic,” said Cubillos-Ruiz.

Preempting evolution: Introducing a bacteria that breaks down antibiotics to the gut is risky.

If a bacteria in the gut “learns” that secreting the beta-lactamase enzyme helps it survive antibiotics, it might swipe the gene that makes that enzyme from the engineered bacteria for itself. That would make it harder to kill the bacteria if we ever need to in the future, increasing the problem of antibiotic resistance

To prevent that, the researchers split the gene that makes the enzyme into two pieces and placed the segments on different pieces of DNA in their engineered bacteria. Another microbe would need to adopt both of these segments independently to produce the enzyme, which is far less likely.

Tests in mice suggest the engineered bacteria won’t interfere with antibiotics’ ability to fight infections outside the gut.

Looking ahead: The researchers are now working to develop their experimental treatment into something that could be tested in people for whom antibiotic-caused dysbiosis is likely to lead to acute diseases.

If human trials go well, their long-term goal is to see the engineered bacteria administered to anyone taking antibiotics for infections outside the gut.

“If the antibiotic action is not needed in the gut, then you need to protect the microbiota … No previous intervention could offer this level of protection,” said Cubillos-Ruiz.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Related
Viruses may one day treat inflammatory bowel disease
Researchers have created a cocktail of viruses that may be able to treat inflammatory bowel diseases like Crohn’s.
Nanoparticle sensor can distinguish between viral and bacterial pneumonia
MIT researchers have designed a sensor that can distinguish between viral and bacterial pneumonia infections.
Yale study finds low levels of a hormone may predict long COVID
Yale and Icahn School of Medicine researchers may have found biomarkers for identifying long COVID.
Cells become zombies when the ends of their chromosomes are damaged
Damage to the ends of the chromosomes can create “zombie cells” that are still alive but can’t function, researchers say.
Only human Lyme vaccine in development enters phase 3 trial
Pfizer and French biotech Valneva have announced a phase 3 clinical trial testing the human Lyme vaccine.
Up Next
Subscribe to Freethink for more great stories